Preclinical News and Research

RSS

EMA recommends orphan designation to Magnus Growth's novel therapy for placental insufficiency

Magnus Life Science today announces that the European Medicines Agency's Committee for Orphan Medicinal Products has reached a positive decision on recommending orphan designation to Magnus Growth's novel therapy to treat placental insufficiency.

8 Jan 2015

Arcturus to exhibit new mRNA therapeutics pipeline at two healthcare conferences

Arcturus Therapeutics Inc., developing the 'next wave' of RNA medicines, today announced that Joseph Payne, President and Chief Executive Officer, is scheduled to present a corporate overview, including the company's new messenger RNA (mRNA) therapeutics pipeline, at two upcoming healthcare conferences.

7 Jan 2015

Novel drug delivery technique uses graphene to deliver two anticancer drugs sequentially to cancer cells

An international team of researchers has developed a drug delivery technique that utilizes graphene strips as "flying carpets" to deliver two anticancer drugs sequentially to cancer cells, with each drug targeting the distinct part of the cell where it will be most effective. The technique was found to perform better than either drug in isolation when tested in a mouse model targeting a human lung cancer tumor.

7 Jan 2015

CytRx reports positive interim results from aldoxorubicin Phase 2 trial for treatment of GBM

CytRx Corporation, a biopharmaceutical research and development company specializing in oncology, today announced positive interim results from its ongoing Phase 2 clinical trial with aldoxorubicin for the treatment of unresectable glioblastoma multiforme (GBM), a deadly form of brain cancer.

6 Jan 2015

Johnson & Johnson begins Phase 1 trial of preventive Ebola vaccine program

Johnson & Johnson today announced the start of a Phase 1, first-in-human clinical trial of a preventive Ebola vaccine in development at its Janssen Pharmaceutical Companies.

6 Jan 2015

Oncoceutics, MD Anderson partner to develop novel anti-cancer drug

Oncoceutics Inc. and The University of Texas MD Anderson Cancer Center today announced the initiation of a strategic alliance and research collaboration agreement for the clinical development of ONC201, a novel anti-cancer drug.

5 Jan 2015

Study: Placental cells may possibly treat damaged nerves

New findings suggest that placental cells may potentially treat damaged nerves possibly leading the way to new treatment for stroke patients.

5 Jan 2015

Tikcro enters into research and license agreement with Yeda

Tikcro Technologies Ltd. today announced that it has entered into a research and license agreement with Yeda Research and Development Company Ltd., the technology transfer arm of the Weizmann Institute of Science in Israel.

30 Dec 2014

Kinex Pharmaceuticals doses first patient with KX2-361 in ‘A Phase 1’ clinical trial

Kinex Pharmaceuticals announced today that the first patient has been dosed with KX2-361 at Roswell Park Cancer Institute.

25 Dec 2014

Bio2 Technologies' CLM Bioactive Scaffold receives FDA clearance

Bio2 Technologies, Inc. (a privately held development stage company) announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration for its CLM Bioactive Scaffold.

19 Dec 2014

New training network project to develop medical statisticians to achieve drug development success

A new £2.7 million international training network project, led by a team at Lancaster University, will develop a generation of medical statisticians dedicated to achieving early stage drug development success.

17 Dec 2014

Investigational drug increases PFS in patients with advanced breast cancer

In a groundbreaking study that offers new hope for women with advanced breast cancer, researchers from UCLA's Jonsson Comprehensive Cancer Center have published final clinical trial results that showed the amount of time patients were on treatment without their cancer worsening (called progression-free survival) was effectively doubled in women with advanced breast cancer who took the experimental drug palbociclib.

17 Dec 2014

Preclinical study strongly supports NT-113 as potential new treatment for glioblastoma multiforme

NewGen Therapeutics, Inc. today announced the publication of preclinical research strongly supporting NT-113, the company's novel irreversible pan-erbB inhibitor (EGFR, HER2 and HER4), as a potential new treatment for glioblastoma multiforme (GBM), the most common and most aggressive malignant primary brain tumor in adults.

16 Dec 2014

Pre-clinical studies confirm TRXE-009 as new potential treatment for melanoma

Novogen Limited, Australian/US biotechnology company, today announces that it has confirmed that its lead candidate product, TRXE-009, originally developed for the treatment of brain cancers, has been shown in pre-clinical studies also to be highly active against melanoma.

16 Dec 2014

Curie-Cancer, GamaMabs Pharma extend partnership to develop 3C23K drug for gynecological cancers

Curie-Cancer, the body responsible for developing Institut Curie’s industry partnership activities, and GamaMabs Pharma, a company specialized in the development of monoclonal antibodies for cancer, today announce the extension of their partnership to develop the 3C23K antibody for the treatment of gynecological cancers.

16 Dec 2014

Sensitive toxicity test aims to detect dangerous side effects in pharmaceutical development

Because of undetected toxicity problems, about a third of prescription drugs approved in the U.S. are withdrawn from the market or require added warning labels limiting their use. An exceptionally sensitive toxicity test invented at the University of Utah could make it possible to uncover more of these dangerous side effects early in pharmaceutical development so that fewer patients are given unsafe drugs.

16 Dec 2014

FL118 agent shows efficacy as personalized, targeted therapy for certain cancer tumors

A team led by Fengzhi Li, PhD, and Xinjiang Wang, PhD, of Roswell Park Cancer Institute has reported new findings regarding therapeutic targets of the novel anticancer agent FL118. Previous studies from these researchers have showed that FL118 induces cancer cell death, or apoptosis, by inhibiting expression of multiple cell-survival proteins (survivin, Mcl-1, XIAP or cIAP2).

15 Dec 2014

ETH Zurich, University of Zurich jointly open new translational research centre

ETH Zurich and the University of Zurich are taking their long-standing partnership to a new level with a new translational research centre. The two universities are founding the Wyss Translational Center Zurich (WTZ) with funds donated by Hansjörg Wyss to the ETH Zurich Foundation.

14 Dec 2014

ALS Association announces research funds to further understand genetic cause of ALS

The ALS Association is pleased to announce the award of $326,662 in research funds to expand ongoing natural history studies in order to further understand the most common genetic cause of ALS, in preparation for clinical trials in those whose disease is affected by this gene.

14 Dec 2014

Figitumumab development discontinued for non-adenocarcinoma NSCLC

Adding the novel insulin-like growth factor 1 receptor inhibitor figitumumab to the epidermal growth factor receptor–tyrosine kinase inhibitor erlotinib does not improve survival in patients with non-adenocarcinoma non-small-cell lung carcinoma, research shows.

12 Dec 2014

Preclinical News and Research

EMA recommends orphan designation to Magnus Growth's novel therapy for placental insufficiency

Arcturus to exhibit new mRNA therapeutics pipeline at two healthcare conferences

Novel drug delivery technique uses graphene to deliver two anticancer drugs sequentially to cancer cells

CytRx reports positive interim results from aldoxorubicin Phase 2 trial for treatment of GBM

Johnson & Johnson begins Phase 1 trial of preventive Ebola vaccine program

Oncoceutics, MD Anderson partner to develop novel anti-cancer drug

Study: Placental cells may possibly treat damaged nerves

Tikcro enters into research and license agreement with Yeda

Kinex Pharmaceuticals doses first patient with KX2-361 in ‘A Phase 1’ clinical trial

Bio2 Technologies' CLM Bioactive Scaffold receives FDA clearance

New training network project to develop medical statisticians to achieve drug development success

Investigational drug increases PFS in patients with advanced breast cancer

Preclinical study strongly supports NT-113 as potential new treatment for glioblastoma multiforme

Pre-clinical studies confirm TRXE-009 as new potential treatment for melanoma

Curie-Cancer, GamaMabs Pharma extend partnership to develop 3C23K drug for gynecological cancers

Sensitive toxicity test aims to detect dangerous side effects in pharmaceutical development

FL118 agent shows efficacy as personalized, targeted therapy for certain cancer tumors

ETH Zurich, University of Zurich jointly open new translational research centre

ALS Association announces research funds to further understand genetic cause of ALS

Figitumumab development discontinued for non-adenocarcinoma NSCLC

Event guide: 4th LNP Formulation & Process Development Summit eBook

Latest eBooks

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics